Top

Applied Health Economics and Health Policy

Published in:

01-04-2015 | Editorial

Biosimilar Versus Generic Drugs: Same But Different?

Authors: Katelijne van de Vooren, Alessandro Curto, Livio Garattini

Published in: Applied Health Economics and Health Policy | Issue 2/2015

Excerpt

Research and development characterizes the pharmaceutical industry, and the flow of new drugs is protected by patents to remunerate this investment. Once a patent expires, price competition is possible, since any manufacturer can copy the originator product. This circumstance justifies the place in the pharmaceutical market for generics and biosimilars, i.e. off-patent medicines to be sold at lower prices than their originators. …

European Medicines Agency. European Public Assessment Reports. Biosimilars. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages%2Fmedicines%2Flanding%2Fepar_search.jsp&mid=WC0b01ac058001d124&searchTab=searchByAuthType&alreadyLoaded=true&isNewQuery=true&status=Authorised&status=Withdrawn&status=Suspended&status=Refused&keyword=Enter+keywords&searchType=name&taxonomyPath=&treeNumber=&searchGenericType=biosimilars&genericsKeywordSearch=Submit. Last accessed 15 Jan 2015.

European Medicines Agency. Questions and answers on generic medicines. 22 November 2012. EMA/393905/2006 Rev 2. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Medicine_QA/2009/11/WC500012382.pdf. Last accessed 9 Dec 2014.

European Medicines Agency. Questions and answers on biosimilar medicines (similar biological medicinal products). 27 September 2012. EMA/837805/2011. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Medicine_QA/2009/12/WC500020062.pdf. Last accessed 9 Dec 2014.

Weise M, Kurki P, Wolff-Holz E, Bielsky MC, Schneider CK. Biosimilars: the science of extrapolation. Blood. 2014;124(22):3191–6.CrossRefPubMed

Bocquet F, Paubel P, Fusier I, Cordonnier AL, Le Pen C, Sinègre M. Biosimilar granulocyte colony-stimulating factor uptakes in the EU-5 Markets: a descriptive analysis. Appl Health Econ Health Policy. 2014;12:315–26.PubMed

Schäfer W, Kroneman M, Boerma W, van den Berg M, Westert G, Devillé W, et al. The Netherlands: health system review. Health Syst Transit. 2010;12(1):5–27, 1–228.

Hassali MA, Wong ZY, Alrasheedy AA, Saleem F, Mohamad Yahaya AH, Aljadhey H. Perspectives of physicians practicing in low and middle income countries towards generic medicines: a narrative review. Health Policy. 2014;117(3):297–310.CrossRefPubMed

Godman B, Shrank W, Wettermark B, Andersen M, Bishop I, Burkhardt T, et al. Use of generics: a critical cost containment measure for all healthcare professionals in Europe? Pharmaceuticals. 2010;3(8):2470–94.CrossRefPubMedCentral

Garattini L, Tediosi F. A comparative analysis of generics markets in five European countries. Health Policy. 2000;51(3):149–62.CrossRefPubMed

10.

Giuliani G, Selke G, Garattini L. The German experience in reference pricing. Health Policy. 1998;44(1):73–85.CrossRefPubMed

11.

Bennett CL, Chen B, Hermanson T, Wyatt MD, Schulz RM, Georgantopoulos P, et al. Regulatory and clinical considerations for biosimilar oncology drugs. Lancet Oncol. 2014;15(13):e594–605.CrossRefPubMed

12.

Blackstone EA, Joseph PF. The economics of biosimilars. Am Health Drug Benefits. 2013;6(8):469–78.PubMedCentralPubMed

13.

Curto A, van de Vooren K, LoMuto R, Duranti S, Garattini L. Regional tenders on biosimilars in Italy, potentially competitive? GaBI J. 2013;2(3):123–9.CrossRef

14.

Ortega E. Medicamentos biológicos de marca y biosimilares competirán en los mismos concursos públicos. Redacción Médica 25th November 2014. http://www.redaccionmedica.com/secciones/industria/biologicos-de-marca-y-biosimilares-competiran-en-los-mismos-concursos-publicos-5934. Last accessed 9 Dec 2014.

15.

US$67 billion worth of biosimilar patents expiring before 2020. 20 January 2014. GaBI Journal. Available from: http://www.gabionline.net/Biosimilars/General/US-67-billion-worth-of-biosimilar-patents-expiring-before-2020. Last accessed 9 Dec 2014.

16.

European Medicines Agency, Committee for Medicinal Products for Human Use (CHMP). Guideline on similar biological medicinal products. 30 October 2005. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003517.pdf. Last accessed 9 Dec 2014.

17.

Brinks V, Hawe A, Basmeleh AH, Joachin-Rodriguez L, Haselberg R, Somsen GW, et al. Quality of original and biosimilar epoetin products. Pharm Res. 2011;28(2):386–93.CrossRefPubMedCentralPubMed

18.

DiMasi JA, Hansen RW, Grabowski HG. The price of innovation: new estimates of drug development costs. J Health Econ. 2003;22(2):151–85.CrossRefPubMed

19.

Curto S, Ghislandi S, van de Vooren K, Duranti S, Garattini L. Regional tenders on biosimilars in Italy: an empirical analysis of awarded prices. Health Policy. 2014;116(2–3):182–7.CrossRefPubMed

Title: Biosimilar Versus Generic Drugs: Same But Different?
Authors: Katelijne van de Vooren
Alessandro Curto
Livio Garattini
Publication date: 01-04-2015
Publisher: Springer International Publishing
Published in: Applied Health Economics and Health Policy / Issue 2/2015
Print ISSN: 1175-5652
Electronic ISSN: 1179-1896
DOI: https://doi.org/10.1007/s40258-015-0154-9

At a glance: The STEP trials

Springer Medicine

Biosimilar Versus Generic Drugs: Same But Different?

Excerpt

At a glance: The STEP trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 2/2015

Measuring the Cost Effectiveness of HIV Prevention Interventions in the US: Pitfalls and Problems

An Estimation of the Value of Informal Care Provided to Dependent People in Spain

The geko™ Electro-Stimulation Device for Venous Thromboembolism Prophylaxis: A NICE Medical Technology Guidance

Cost-Effectiveness and Value of Information Analysis of Nutritional Support for Preventing Pressure Ulcers in High-risk Patients: Implement Now, Research Later

Prospective Randomized Controlled Trial Comparing the Outcomes and Costs of Two Eyecare Adherence Interventions in Diabetes Patients

A Systematic Review on Cost Effectiveness of HIV Prevention Interventions in the United States